PepGen (PEPG) announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company. Ms. Wyman was recently appointed Chief Technical and Quality Officer at Scholar Rock (SRRK). Dr. Finer is a co-founder and Strategic Advisor for ElevateBio, where he previously served as President of Research and Development and as Chief Executive Officer of Life Edit Therapeutics, its gene editing business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEPG:
- PepGen Inc. Faces Clinical Trial Challenges and Competitive Pressures Leading to Sell Rating
- PepGen to pause CONNECT2-EDO51 study
- Promising Prospects for PepGen Inc.: Buy Rating Affirmed Amid Positive DM1 Treatment Developments
- Biotech Alert: Searches spiking for these stocks today
- PepGen Inc. Reports Positive Trial Results and Financials